CLBS - CLBS STOCK NEWS

Caladrius Biosciences, Inc. (Nasdaq: CLBS) announced its participation in several upcoming industry events, including the Biotech Showcase and H.C. Wainwright BioConnect Conference, both scheduled for January 2022 and held virtually. Presentations will be led by David J. Mazzo, PhD, President and CEO, and will be available on-demand. The company focuses on developing innovative therapies to treat diseases, with product candidates like XOWNA (CLBS16) for coronary microvascular dysfunction and CLBS12 for Buerger's Disease.

Caladrius Biosciences, Inc. (Nasdaq: CLBS) reported a robust cash position of approximately $100 million as of September 30, 2021, enabling continued focus on its clinical programs despite COVID-19 challenges. The company is preparing to initiate a Phase 1 trial for CLBS201, targeting diabetic kidney disease, with enrollment projected for Q1 2022. R&D expenses increased by 36% to $4.1 million, with net losses rising to $6.9 million from $5.3 million year-over-year. The company aims to identify additional development assets to enhance shareholder value.

Caladrius Biosciences (CLBS) announced it will report its financial results for the three months ended September 30, 2021, on November 4, 2021, at 4:30 p.m. ET. The company focuses on developing cellular therapies aimed at reversing diseases, with its current product candidates including XOWNA (CLBS16) and CLBS12 (HONEDRA) targeting coronary microvascular dysfunction and critical limb ischemia, respectively. XOWNA recently completed a positive Phase 2a study and is now advancing to a Phase 2b study. For those unable to attend the live conference call, a replay will be available.

Caladrius Biosciences (Nasdaq: CLBS), a clinical-stage biopharmaceutical company, announced its participation in key industry events during October 2021. Notably, they will present at the UK Kidney Week Virtual Conference on October 4 and at the Advanced Therapies Congress & Expo on October 5, focusing on new therapy targets for kidney disease and industry learnings during COVID-19. The company will also be featured in the LD Micro Main Event from October 12-14, and the Dawson James Securities Small Cap Growth Conference on October 20-21. These presentations aim to showcase their innovative cellular therapies for diseases.

Caladrius Biosciences (Nasdaq: CLBS) announced that CEO David J. Mazzo will present a corporate update and hold investor meetings at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The presentation will be available on-demand starting September 13 at 7:00 a.m. ET. The company focuses on developing cellular therapies to reverse diseases, with key product candidates including CLBS16 and CLBS12, which target coronary microvascular dysfunction and critical limb ischemia. For more details, visit caladrius.com.

Bryn Pharma has appointed Anne Clem Whitaker to its Board of Directors, effective immediately. With over 30 years of leadership experience in pharmaceuticals and medical devices, Whitaker previously served as CEO of Aerami Therapeutics and held executive roles at Sanofi and GlaxoSmithKline. CEO David Dworaczyk expressed optimism about her contributions toward advancing Bryn's innovative treatment for anaphylaxis. Bryn aims to disrupt the epinephrine autoinjector market by providing a more accessible, user-friendly alternative.

Caladrius Biosciences (Nasdaq: CLBS) announced the appointment of Dr. Kristen K. Buck as Chief Medical Officer. Dr. Buck, previously CMO at ICON, brings extensive experience in drug development across various therapeutic areas. Her leadership is expected to advance Caladrius' clinical development programs, particularly in cellular therapies aimed at reversing diseases like ischemic conditions. Dr. Buck sees significant potential in Caladrius' CD34+ cell therapy technology, aiming for clinical and commercial success while enhancing shareholder value.

Caladrius Biosciences (CLBS) reported positive operational and financial results for Q2 2021, despite COVID-19 challenges. The company is progressing with its Phase 2b FREEDOM Trial for CLBS16, targeting coronary microvascular dysfunction, and plans to initiate a Phase 2 trial for CLBS201, which addresses diabetic kidney disease. Strong cash reserves of $106.1 million ensure funding for ongoing studies. However, the timeline for clinical trials may extend due to pandemic-related enrollment issues. The company remains optimistic about its projects and partnerships aimed at advancing its pipeline.

Caladrius Biosciences (Nasdaq: CLBS) will report its financial results for Q2 2021 on August 5, 2021, at 4:30 p.m. ET. The company focuses on developing cellular therapies to reverse diseases, including products like CLBS16, which has positive Phase 2a study results and a new Phase 2b study for treating coronary microvascular dysfunction. Other candidates include CLBS12 and CLBS201, with ongoing clinical trials. Investors can join the conference call via dial-in or webcast, with a replay available for 90 days.